Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome
- PMID: 16768644
- DOI: 10.1089/cap.2006.16.365
Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome
Abstract
Atomoxetine and OROS methylphenidate were successfully used concomitantly in a 10-year-old boy suffering from attention-deficit/hyperactivity disorder (ADHD) with comorbid bipolar disorder and Tourette syndrome (TS). The child received valproic acid, clonidine, and ziprasidone concurrently. Because possible side effects of pharmacological treatment for one diagnosis may exacerbate a comorbid condition, contingent management strategies, when using polypharmacy, are mandated.
Similar articles
-
Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.Eur Child Adolesc Psychiatry. 2006 Feb;15(1):1-11. doi: 10.1007/s00787-006-0505-z. Eur Child Adolesc Psychiatry. 2006. PMID: 16514504 Review.
-
Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18. Expert Rev Neurother. 2011. PMID: 21469923
-
Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.J Manag Care Pharm. 2007 Sep;13(7):561-9. doi: 10.18553/jmcp.2007.13.7.561. J Manag Care Pharm. 2007. PMID: 17874862 Free PMC article.
-
Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.J Am Acad Child Adolesc Psychiatry. 2009 Sep;48(9):884-893. doi: 10.1097/CHI.0b013e3181b26e9f. J Am Acad Child Adolesc Psychiatry. 2009. PMID: 19625978 Free PMC article.
-
Tourette Syndrome and comorbid ADHD: current pharmacological treatment options.Eur J Paediatr Neurol. 2013 Sep;17(5):421-8. doi: 10.1016/j.ejpn.2013.01.005. Epub 2013 Mar 7. Eur J Paediatr Neurol. 2013. PMID: 23473832 Review.
Cited by
-
Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.CNS Drugs. 2009 Sep;23(9):739-53. doi: 10.2165/11314350-000000000-00000. CNS Drugs. 2009. PMID: 19689165 Review.
-
Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.Behav Brain Res. 2013 May 1;244:38-47. doi: 10.1016/j.bbr.2013.01.027. Epub 2013 Jan 31. Behav Brain Res. 2013. PMID: 23376704 Free PMC article.
-
Off-label use of atomoxetine in adults: is it safe?Ment Illn. 2012 Sep 24;4(2):e19. doi: 10.4081/mi.2012.e19. eCollection 2012 Jul 26. Ment Illn. 2012. PMID: 25478120 Free PMC article. Review.
-
Atomoxetine and stimulant medications in children and adolescents with persistent symptoms of attention deficit hyperactivity disorder despite monotherapy.Can Pharm J (Ott). 2012 Sep;145(5):226-230.e1. doi: 10.3821/145.5.cpj226. Can Pharm J (Ott). 2012. PMID: 23509571 Free PMC article. No abstract available.
-
ADHD-juvenile bipolar disorder: mimics and chameleons!World J Pediatr. 2018 Dec;14(6):525-527. doi: 10.1007/s12519-018-0124-z. Epub 2018 Feb 14. World J Pediatr. 2018. PMID: 29446039 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical